吡格列酮对2型糖尿病病人血糖控制的疗效和安全性分析

目的：研究并探讨吡格列酮对2型糖尿病患者血糖控制的疗效及安全性.方法：于2013年1月-2015年12月,选取我院收治的100例2型糖尿病患者作为此次研究的对象,采取数字随机表法将患者分为对照组、观察组,每组50例.对照组采用二甲双胍治疗,观察组在二甲双胍治疗的基础上加用吡格列酮.比较两组患者的血糖变化情况、不良反应发生情况.结果：治疗后,两组患者的血糖水平均较治疗前明显降低（P〈0.05）,但观察组的血糖水平较对照组明显更低（P〈0.05）.两组患者的不良反应发生率比较,差异无统计学意义（P〉0.05）.结论：采用吡格列酮治疗2型糖尿病,可有效控制患者的血糖,且安全性较高.

Objective： To study and explore the efficacy and safety of pioglitazone on glycemic control in type 2 diabetic patients. Methods： In January 2013 to December 2015, 100 cases of type 2 diabetic patients in the hospital were selected as the research object, the patients were divided into the control group and the observation group by taking the random number table approach, each group had 50 cases. The control group was given metformin treatment, the observation group was treated with pioglitazone and metformin. The changes of blood glucose and adverse reactions were compared between the two groups. Results： After treatment, the blood glucose levels of the two groups were significantly lower than before treatment （P〈0.05）, but the blood glucose level in the observation group was significantly lower than that in the control group （P〈0.05）. The incidence of adverse reactions in two groups were compared, and the difference was not statistically significant （P〉0.05）. Conclusion： The using of pioglitazone in treatment of type 2 diabetes can effectively control blood glucose, and have high safety.